Aspirin's colon cancer prevention limited

Share this article:
Gene Mutation Influences Aspirin's Colon Cancer Benefit
Gene Mutation Influences Aspirin's Colon Cancer Benefit

(HealthDay News) -- Regular aspirin use is associated with a lower risk of developing colorectal cancer, but only cancers without mutations in the BRAF oncogene, according to a study published in the June 26 issue of the Journal of the American Medical Association.

Reiko Nishihara, Ph.D., from the Dana-Farber Cancer Institute in Boston, and colleagues analyzed data from 127,865 participants in two large studies to examine the association between aspirin intake and colorectal cancer risk based on the presence of tumor mutations in the BRAF oncogene.

The researchers found that there were 1,226 incident rectal and colon cancers during follow-up. After adjusting for various factors, regular aspirin use was associated with a lower risk of BRAF-wild-type cancer (hazard ratio [HR], 0.73) but not BRAF-mutated cancer (HR, 1.03). The association was unaffected by the status of tumor prostaglandin-endoperoxide synthase 2 expression or PIK3CA or KRAS mutation. Increasing the number of aspirin tablets per week lowered the risk of BRAF-wild-type cancer (HR, 0.43 for >14 tablets per week), while more tablets had no effect on the risk of BRAF-mutated cancer.

"Regular aspirin use was associated with lower risk of BRAF-wild-type colorectal cancer but not with BRAF-mutated cancer risk," Nishihara and colleagues conclude. "These findings suggest that BRAF-mutant colon tumor cells may be less sensitive to the effect of aspirin."

One author has been a consultant for several pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor parent-provider communication seen in advanced pediatric cancer

Poor parent-provider communication seen in advanced pediatric cancer

For pediatric patients with advanced cancer, parent-provider concordance is poor regarding prognosis and goals of care, according to a study.

Testicular cancer on the rise for young U.S. Hispanics

Testicular cancer on the rise for young U.S. ...

An increase in incidence of testicular germ cell tumors in Hispanic adolescents and young adults in the United States has been observed.

Rates of observation as prostate cancer management vary

Rates of observation as prostate cancer management vary

Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.